Rekah Pharmaceutical Industry Ltd (REKA) — Cash Flow Reinvestment Rate
Rekah Pharmaceutical Industry Ltd (REKA) has a Cash Flow Reinvestment Rate of 0.04x as of June 2026, reinvesting ILA495.00K (capex ILA495.00K ) from operating cash flow of ILA13.82 Million. See Rekah Pharmaceutical Industry Ltd (REKA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Rekah Pharmaceutical Industry Ltd Cash Flow Reinvestment Rate (2002–2025)
Historical reinvestment intensity for Rekah Pharmaceutical Industry Ltd across 21 annual periods. For the full cash flow conversion analysis, see Rekah Pharmaceutical Industry Ltd (REKA) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for Rekah Pharmaceutical Industry Ltd (2002–2025)
Year-by-year capital reinvestment analysis for Rekah Pharmaceutical Industry Ltd. See Rekah Pharmaceutical Industry Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (ILA) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.58x | ILA7.47 Million | ILA12.95 Million | ILA7.03 Million | ▲ +73.1% |
| 2024 | 0.33x | ILA8.85 Million | ILA26.54 Million | ILA8.70 Million | ▼ -18.3% |
| 2023 | 0.41x | ILA11.57 Million | ILA28.35 Million | ILA11.49 Million | ▼ -24.0% |
| 2022 | 0.54x | ILA20.93 Million | ILA39.00 Million | ILA7.48 Million | ▼ -35.6% |
| 2021 | 0.83x | ILA17.65 Million | ILA21.17 Million | ILA13.99 Million | ▼ -58.2% |
| 2020 | 1.99x | ILA22.49 Million | ILA11.28 Million | ILA18.84 Million | ▲ +37.8% |
| 2019 | 1.45x | ILA49.05 Million | ILA33.91 Million | ILA45.40 Million | ▲ +60.1% |
| 2018 | 0.90x | ILA15.61 Million | ILA17.28 Million | ILA15.18 Million | ▲ +20.9% |
| 2017 | 0.75x | ILA17.77 Million | ILA23.80 Million | ILA16.48 Million | ▼ -37.0% |
| 2016 | 1.19x | ILA27.08 Million | ILA22.82 Million | ILA13.44 Million | ▼ -54.1% |
| 2015 | 2.59x | ILA15.02 Million | ILA5.81 Million | ILA13.15 Million | ▼ -84.2% |
| 2014 | 16.32x | ILA21.71 Million | ILA1.33 Million | ILA19.27 Million | ▲ +4180.1% |
| 2013 | 0.38x | ILA4.46 Million | ILA11.71 Million | ILA4.38 Million | ▼ -44.9% |
| 2012 | 0.69x | ILA9.82 Million | ILA14.18 Million | ILA9.82 Million | ▼ -40.8% |
| 2010 | 1.17x | ILA7.87 Million | ILA6.73 Million | ILA7.87 Million | ▲ +226.1% |
| 2009 | 0.36x | ILA9.33 Million | ILA26.03 Million | ILA9.33 Million | ▼ -78.0% |
| 2008 | 1.63x | ILA10.73 Million | ILA6.57 Million | ILA10.73 Million | ▲ +285.0% |
| 2007 | 0.42x | ILA5.28 Million | ILA12.45 Million | ILA5.28 Million | ▼ -74.4% |
| 2005 | 1.66x | ILA7.09 Million | ILA4.27 Million | ILA7.09 Million | ▲ +530.7% |
| 2004 | 0.26x | ILA4.70 Million | ILA17.87 Million | ILA4.70 Million | ▲ +20.9% |
| 2002 | 0.22x | ILA2.44 Million | ILA11.21 Million | ILA2.44 Million | — |